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Identification of a Novel, Small 
Molecule Partial Agonist for the 
Cyclic AMP Sensor, EPAC1
Euan Parnell1, Stuart P. McElroy2, Jolanta Wiejak3, Gemma L. Baillie2, Alison Porter2, David R. 
Adams4, Holger Rehmann5, Brian O. Smith1 & Stephen J. Yarwood3
Screening of a carefully selected library of 5,195 small molecules identified 34 hit compounds that 
interact with the regulatory cyclic nucleotide-binding domain (CNB) of the cAMP sensor, EPAC1. Two of 
these hits (I942 and I178) were selected for their robust and reproducible inhibitory effects within the 
primary screening assay. Follow-up characterisation by ligand observed nuclear magnetic resonance 
(NMR) revealed direct interaction of I942 and I178 with EPAC1 and EPAC2-CNBs in vitro. Moreover, in 
vitro guanine nucleotide exchange factor (GEF) assays revealed that I942 and, to a lesser extent, I178 
had partial agonist properties towards EPAC1, leading to activation of EPAC1, in the absence of cAMP, 
and inhibition of GEF activity in the presence of cAMP. In contrast, there was very little agonist action 
of I942 towards EPAC2 or protein kinase A (PKA). To our knowledge, this is the first observation of non-
cyclic-nucleotide small molecules with agonist properties towards EPAC1. Furthermore, the isoform 
selective agonist nature of these compounds highlights the potential for the development of small 
molecule tools that selectively up-regulate EPAC1 activity.
The exchange protein activated by cAMP (EPAC) isoforms, EPAC1 and EPAC2, are guanine nucleotide exchange 
factors (GEFs) for the Ras GTPase homologues, Rap1 and Rap2, which they activate independently of the classi-
cal cAMP-sensing enzyme, protein kinase A (PKA)1. As such, EPACs represent a novel means through which the 
ubiquitous second messenger, cAMP, can exert control over cell activity.
We have previously defined a role for EPAC1 in cAMP mediated, PKA-independent transcriptional induction 
of the suppressor of cytokine signalling 3 (SOCS3) gene, which occurs through the activation of C/EBP transcrip-
tion factors in vascular endothelial cells (VECs)2, 3. Classically, SOCS3 induction occurs in response to inflam-
matory cues, such as interleukin 6 (IL6) stimulation, with subsequent activation of the JAK-STAT signalling 
pathway4. SOCS3 is then able to bind to JAK-phosphorylated receptors via the SOCS3 SH2 domain, inhibiting 
the activation of STATs 1 and 3 by JAK5. Furthermore, SOCS3 is able to direct the proteasomal degradation5 of 
various proteolytic targets, including JAK26, resulting in a negative feedback loop that attenuates inflammatory 
signalling from the IL-6 receptor2, 7, 8.
Recent work has suggested that EPAC1 and SOCS3 may also play a key role in the central control of energy 
balance. For example, leptin has also been shown to induce SOCS3 expression in INS-1 β-cells and human pan-
creatic islets in vitro and in the pancreatic islets of obsese, ob/ob, mice in vivo9, where it inhibits STAT3-dependent 
rat preproinsulin 1 gene promoter activity9. Taken together, these observations suggest that there may be a link 
between SOCS3 induction and the development of type 1 and type 2 diabetes (T2D). Indeed, it has been shown 
that SOCS3 may be involved in the development of insulin resistance, normally associated with T2D. This it 
thought to occur through the disruption of insulin receptor (IR) signalling to phosphoinositide 3-kinase (PI3K) 
and the mitogen activated protein kinase, ERK, through its key intracellular substrate, insulin receptor substrate 1 
(IRS-1)10. In this case, increased SOCS3 levels inhibit IR tyrosine phosphorylation on Tyr 960, thereby preventing 
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coupling to IRS-111. IRS-1 is then targeted for proteosomal degradation thereby preventing down-stream signal-
ling to PI3K and ERK and preventing the metabolic actions of insulin12, 13.
Clearly, the potential for EPAC1/SOCS3 signalling to regulate inflammation7, 8 and leptin14, 15 and insulin sig-
nalling indicates that EPAC1 may be a valid drug target for a range of disease states16. Indeed, this has prompted 
a number of laboratories to use high throughput screening (HTS) of compound libraries to search for small 
molecule regulators of EPAC activity17–20. Arguably, the most successful of these HTS strategies involved the 
use of the fluorescent cAMP analogue, 8-NBD-cAMP, to screen for competitive inhibitors of full-length EPAC2, 
leading to the discovery of the EPAC2-selective inhibitor, ESI-05 (4-Methylphenyl-2,4,6-trimethylphenyls
ulfone)21. Similarly, a non-selective EPAC1 and EPAC2 inhibitor, ESI-09 (3-(5-tert-butyl-isoxazol-3-yl)-2-
[(3-chloro-phenyl)-hydrazonol]-3-oxo-propionitrile), was identified by similar protocols22–24, however, con-
cerns have been raised about the mechanisms of action of this compound, which has been suggested to display 
non-specific protein denaturing properties25. Interestingly, HTS using 8-NBD-cAMP competition assays has 
been limited to screens involving EPAC2, likely due to the limited fluorescence of 8-NBD-cAMP when bound 
to the cyclic nucleotides binding domain (CNB) of EPAC1 compared to EPAC219. This difference may be linked 
to structural differences between EPAC1 and EPAC2 within the CNB that influences the selective docking of 
ligands to the cAMP-binding pocket26. Both uncompetitive (CE3F4) and non-competitive EPAC1 inhibitors 
(5225554 and 5376753) have also been identified through HTS using an in vitro EPAC1 GEF activity assay18 and 
an EPAC-based bioluminescence resonance energy transfer-based assay17, respectively. Notably, none of these 
HTS approaches has isolated small molecule agonists of EPAC activity, the identification of which would provide 
important tools to probe the mode of action of EPAC in multiple disease states.
In the current study, we used the isolated CNBs of EPAC1 and EPAC2 to develop a robust 8-NBD-cAMP com-
petition assay to identify compounds that interact with EPAC1. This is the first report of the use of EPAC1 in HTS 
and the success of the approach was confirmed by the identification of novel ligands (I942 and I178) with partial 
agonist activity towards EPAC1, but not EPAC2. To the best of our knowledge, this compound represents the first 
non-cyclic nucleotide ligand to display agonist properties towards EPAC proteins. Furthermore, the potential to 
activate EPAC1 activity, independently of EPAC2, may facilitate the development of effective EPAC1-targetted 
therapeutic agents. We therefore identified a novel experimental tool to investigate the role of EPAC1 in health 
and disease.
Results
High Throughput Screening (HTS) of Small Molecular Regulators of EPAC1. A fluorescence-based 
HTS assay based on the displacement of the fluorescent cAMP analogue, 8-NBD-cAMP, from full-length, recom-
binant EPAC2, has proven to be an effective method for the identification of EPAC-selective small molecule 
antagonists of EPAC activity21. Our objective was to modify this approach to identify new regulators of EPAC1 
activity. In order to develop the 8-NBD-cAMP competition assay for HTS of EPAC1, the isolated cyclic nucleo-
tide-binding domain (CNB) of EPAC1 was used, since this fragment contains the key cAMP-regulated, activation 
domain for EPAC1 and displays greater solubility compared to full-length recombinant EPAC127. We therefore 
carried out large-scale recombinant protein purification of the CNBs of EPAC1 (amino acids 169–314) and 
EPAC2 (amino acids 304–453, incorporating the functional second CNB of EPAC2), resulting in the production 
of soluble, 50 kDa proteins (Supplemental Figure 1) corresponding to either GST-EPAC1-CNB (EPAC1-CNB) or 
GST-EPAC2-CNB (EPAC2-CNB).
To validate the folding and suitability of EPAC-CNBs for HTS, we incubated either GST, EPAC1-CNB or 
EPAC2-CNB with 8-NBD-CAMP and measured the resulting fluorescence intensities (485/515 nm, ex/em). In 
agreement with published data27, the fluorescence produced by 8-NBD-cAMP was significantly increased in the 
presence of EPAC1-CNB and EPAC2-CNB, with no change observed with GST alone or in the absence of pro-
tein (Fig. 1a). Therefore, changes in 8-NBD-cAMP occur as a direct result of interaction with either EPAC-CNB 
and not with the GST tag. However, as described previously for full length, recombinant EPAC221, EPAC2-CNB 
promoted a greater increase in fluorescence (6.94 fold) than EPAC1-CNB (2.62 fold, Fig. 1a). The change in 
fluorescence was considerably lower than previously described in the presence of the full length EPAC2 protein, 
although is consistent with previous reports using the isolated CNB of EPAC219. We suggest that the isolated 
CNBs display intrinsic disordered characteristics, altering the protein-probe complex stability or the hydro-
phobic environment favourable to 8-NBD-cAMP fluorescence. To confirm that increases in 8-NBD-cAMP 
fluorescence were a direct result of a specific interaction, the fluorescence intensity was measured in the pres-
ence or absence of saturating concentrations of cAMP. We found that incubation of EPAC-CNBs with cAMP 
(1 mM) reduced 8-NBD-cAMP fluorescence to basal levels due to the displacement of 8-NBD-cAMP from the 
hydrophobic cAMP binding pockets of EPAC1 and EPAC2 CNB, indicating a competitive mode of binding 
(Fig. 1a). To optimise protein-ligand interactions and increase fluorescence intensity for the EPAC1-CNB assay 
we varied buffer pH and ionic strength of the assay buffer (Supplementary Figure 2a) and determined opti-
mal concentrations of both EPAC1-CNB protein and 8-NBD-cAMP probe to use with these optimised assay 
buffer conditions (Supplementary Figure 2b). The lowest concentrations of protein (0.8 µM) and 8-NBD-cAMP 
(62.5 nM to 0.5 µM) which produced a minimum three fold S/B were selected in order to maximise hit detection 
(Supplementary Figure 2b). We also carried out quality control tests using these optimised conditions and found 
that the EPAC1-CNB competition assay displayed excellent stability up to 72 hours after initial mixing of protein 
and probe and a minimum incubation period of four hours was chosen to ensure a stable signal was observed 
and minimise well variability (Supplementary Figure 3a). The assay was stable in the presence of DMSO concen-
trations under 1% (v/v), as normally required for compound library screening (Supplementary Figure 3b). In 
addition, intra- and inter-384-well plate variability was low, indicating high reproducibility within and between 
plates (Supplementary Figures 4 and 5). Under these conditions, a probe concentration of 62.5 nM resulted in IC50 
values that most accurately reflected the published affinities of each compound (Fig. 1b)28. The inhibitory profiles 
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of cAMP, 007 and 8-CPT (Fig. 1b) reveal that this probe concentration allows the identification of competitor 
compounds with a relatively broad range of affinities.
HTS of Small Molecule Competitors of 8-NBD-cAMP-binding to the EPAC1-CNB. Having opti-
mised assay conditions for EPAC1-CNB HTS, 5195 small molecules from the commercially available BioAscent 
Compound Cloud of diverse lead like structures were screened at 10 µM, to identify novel EPAC1-interacting 
compounds. The screen performed well, displaying acceptable signal and variability throughout with consistent 
maximum and minimum control responses, Z’ values ranging from 0.63 to 0.83 and S/B ratios from 4.5 to 4.9 
(Fig. 2). All percentage coefficient of variance (%CV) values were below 7%, indicating satisfactory inter-plate 
and inter-day variability. Using a 15% inhibition cut-off for 8-NBD-cAMP fluorescence in the assay, the screen 
produced a 0.64% hit rate and identified 33 compounds as potential inhibitors of 8-NBD-cAMP binding to the 
EPAC1-CNB (Fig. 2; red dots). Any compounds showing values significantly below the x-axis (>3 SD below) 
in Fig. 2 are very likely to be fluorescent in the 8-NBD-cAMP competition assay. The 33 potential hits were 
then tested in the EPAC1-CNB binding assay using a 7-point, 1 in 3 dilution series, with a 30 µM maximum 
compound concentration, and a final DMSO concentration of 0.75% (v/v). Two compounds were confirmed as 
demonstrating effective reduction of the fluorescence signal (I288 and I178; Fig. 2) and were used to identify a 
further 32 structurally related compounds from the larger BioAscent library of 120,000 compounds (results not 
shown). These compounds were then tested for potency in dose response format (30 µM top concentration and 
final DMSO concentration of 0.5%). This screen identified a further compound, I942, that, similar to I288 and 
I178, produced a dose-dependent reduction (75 µM top concentration) of 8-NBD-cAMP fluorescence in the 
Figure 1. 8-NBD-cAMP Competition Assay Using Purified EPAC1-CNB and EPAC2-CNB Proteins. (a)
The 8-NBD-cAMP competition assay was carried out as previously described19. Briefly, purified EPAC1-CNB 
(0.8 µM), EPAC2-CNB (0.8 µM), GST (0.8 µM) or assay buffer (no protein) was incubated in the presence of 
cAMP (50 µM) or DMSO. 8-NBD-cAMP (0.1 µM) was then added to every well and the fluorescence intensity 
was measured after four hours. Significant inhibition of fluorescence in the presence of cAMP is indicated, 
#P < 0.0001 (n = 3). (b) Inhibition of 8-NBD-cAMP (62.5 nM) fluorescence, resulting from interaction with 
EPAC1-CNB (0.8 µM), is plotted in the presence of varying concentrations of known competitor compounds; 
cAMP (red squares), 007 (blue circles) or 8-CPT (green triangles). IC50 values were calculated for each 
competition assay and are shown in comparison with published Kd values for each competitor.
www.nature.com/scientificreports/
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EPAC1-CNB assay (Fig. 3). Moreover, neither I942 nor I178 displayed auto-fluorescence in the range of con-
centrations used in these assays (Supplementary Figure 6). Thus, the relative IC50 values measured were approx-
imately 70 μM, 40 μM and 35 μM, for I178, I288 and I942 respectively, compared to an IC50 of around 4 μM, for 
cAMP under the same conditions (Fig. 1b). In these experiments, a non-active compound, I516, served as a nega-
tive control and produced an IC50 value of greater than 70 μM. These results suggest that I178, I288 and I942 com-
petitively inhibit 8-NBD-cAMP binding to the EPAC1-CNB, with I942 proving to be the most potent competitor.
Effects of I942 and I178 on EPAC1 and EPAC2 GEF activity in vitro. We next characterised the effects 
of I178, I288, I516 and I942 on EPAC catalytic activity in vitro. For this, we used the well-characterised EPAC GEF 
activity assay29. The assay is based on the EPAC-stimulated dissociation of fluorescent MANT-GDP from recom-
binant Rap1 in the presence of excess non-fluorescent nucleotide. Addition of 500 μM cAMP promoted a robust 
increase in EPAC1 activity, demonstrated by an accelerated decay in MANT-GDP signal over time. In agreement 
with the 8NBD-cAMP competition assays (Fig. 3), cAMP-induced EPAC1 activity was reduced in the presence of 
I942 and, to a lesser extent, I178 and I288 (Fig. 4a). The inhibitory effect of I288 was weaker than that of I178. I516 
has no detectable inhibitory effect. To examine further the weak inhibitory effects of I178 and I288, activity assays 
were carried out using 500 μM I178 and I288 in the presence of 50 μM cAMP (Fig. 4b). Under these conditions, 
EPAC1 is not fully saturated with cAMP and thus the cAMP induced activity is weaker as observed with 500 μM, 
as used in Fig. 4a. With the inhibitors being applied at 10 fold higher concentration than cAMP, inhibition of 
EPAC1 was also observed for I178 and I288, despite their weaker affinities (Fig. 4b).
Interestingly, in the absence of cAMP, I178, I288 and, in particular, I942 also induced EPAC1 activity (Fig. 4a and b). 
To explore this further, the dependency of EPAC1 activity on various concentrations of cAMP, I942 and I178 
was analysed (Fig. 4c). Quasi-saturation was reached for both compounds and AC50 values of 40 μM, 50 μM and 
200 μM were determined for cAMP, I942 and I178, respectively. The AC50 values are basically identical to the Kd 
under the chosen experimental conditions29. Thus cAMP and I942 bind EPAC1 with approximately the same 
affinity, which is greater than that of I178. However, the maximal activity induced by I942 is around 10 fold lower 
than that of cAMP (Fig. 4c). In agreement with this, I942 and I178 inhibits cAMP-induced activation of EPAC1 in 
a concentration dependent manner (Fig. 4c; right panel). In the presence of 500 μM cAMP a half maximal inhi-
bition is observed at about 300 μM I942, which is roughly at equimolar concentrations. This data strongly suggest 
that I942 and cAMP compete for binding to the CNB domain with similar affinities.
We next sought to assess whether I942 and I178 also regulate EPAC2 activity and found that I942 and I178 
inhibited cAMP induced activation of EPAC2280–993, with I942 being the most potent inhibitor (Fig. 5). The affin-
ity of Epac2280–993 for cAMP is 2 μM26, 30, roughly 10 times higher than that of EPAC1. As such experiments were 
Figure 2. Single Point Testing for Compounds Capable of Disrupting. Interaction between EPAC1-CNB and 
8-NBD-cAMP in HTS Compounds from the BioAscent library of diverse lead like structures were assessed in 
384 well plates at 10 µM with 0.25% DMSO final, n = 1 over two testing days. Responses (% effect) from each 
compound tested are shown. For the screen a selection cut-off of 15% was calculated using the median plus 
three times the robust standard deviation (scaled median absolute deviation) of the percentage inhibition across 
all compound wells, generating 33 hits (indicated with red dots) and a 0.67% hit rate. The screen performed 
extremely well with consistent levels of maximum (Max) and minimum (Min) control responses, Z’ values and 
S/B ratios. %CV values were calculated for matching control wells as described (materials and methods) and 
were below 10%, indicating excellent inter-plate and inter-day variability.
www.nature.com/scientificreports/
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performed at 50 μM cAMP instead of 500 μM cAMP as was used for EPAC1 (Fig. 4). In this case, I942 and I178 
induced EPAC2 activity is very weak (Fig. 5b and c). This rather small activity does not allow the determination 
of the affinity of I942 and I178 for EPAC2 from a titration monitoring the activation of EPAC2. However, in the 
presence of 50 μM cAMP, I942 inhibits Epac2280–993 with an IC50 of about 100 μM, compared to 250 μM for I178 
(Fig. 5d). This is at a concentration slightly higher than equi-molarity. Thus, the affinity of I942 for EPAC2280–993 
might be approximated to be 5 μM. If the affinities of I942 for EPAC1 and EPAC2 are put in relation to the affini-
ties of cAMP, one can conclude that I942 inhibits both EPAC proteins with similar efficiency. The agonist action 
of I942 on EPAC2 is, however, smaller than that towards EPAC1, suggesting isoform selective partial-agonism. 
Such differences between EPAC1 and EPAC2 are also observed with cAMP analogues26. The partial agonism 
Figure 3. Dose Response Testing of Hits against EPAC1-CNB. The three hit compounds isolated from the 
Bioascent libraries (structures and molecular weights are shown on the left) were tested in a 7-point dose 
response format (75 µM top concentration, 1 in 2 serial dilution, n = 6 on one plate) alongside a non-binding 
compound (I516) in the EPAC1-CNB, 8-NBD-cAMP binding assay with final DMSO concentration of 0.75%. 
IC50 values are shown in the individual graphs.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 294  | DOI:10.1038/s41598-017-00455-7
Figure 4. GEF activity of EPAC1. (a) Time trace of the exchange reaction with 500 μM cAMP either 500 μM 
I178, I288, I516 or I942 where indicated. The data are fitted as single exponential decay with off-set (red lines) 
to obtain the rate constants kobs, as shown in (b). Rate constants from exchange reactions with either 500 μM 
or 50 μM cAMP, the presence or absence of 500 μM I178, I288, I516 or I942, as indicated, are presented as 
a bar graph (n = 4). (c) Exchange activity induced by cAMP, I942 or I178. The dependency of kobs on the 
concentration of cAMP (open triangles), I942 (closed circles) or I178 (open circles) is plotted on the left. The 
lower panel shows a magnification of the I942 and I178 induced activity. Inhibition of cAMP induced exchange 
activity by I942 and I178 is shown on the right. kobs were determined in the presence of 500 μM cAMP and 
various concentrations of I942 or I178.
www.nature.com/scientificreports/
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towards EPAC1 does not appear to also extend to PKA. We measured the effects of a range of concentrations 
of I942 on PKA activity induced by 1 mM cAMP, in cell extracts. This was done in comparison with the gen-
eral PKA-inhibitor, H-89. We found that while H-89 treatment exerted a dose-dependent inhibition of PKA 
in cell extracts, whereas I942 did not significantly affect PKA activity, even at a test concentration of 100 μM 
(Supplementary Figure 7). It appears that the actions of I942 are selective towards the CNBs of EPAC proteins.
Verification of interaction of compounds I942 and I178 with EPAC-CNBs by Ligand Observed 
Nuclear Magnetic Resonance (NMR). Given that I942 seems to exert selective agonist properties against 
EPAC1, but not EPAC2, we next sought to validate whether our isolated ligands can interact with EPAC1 and 
EPAC2. Ligand observed nuclear magnetic resonance (NMR) is a valuable tool for the identification and valida-
tion of small molecule ligands31. We therefore used one dimensional proton (1D) and water-ligand observed by 
gradient spectroscopy (waterLOGSY) NMR to confirm the ability of I942 and I178 to bind to the purified CNBs 
of EPAC1 and EPAC2, in comparison with the commercially available EPAC1 antagonist, ESI-0932. In order to 
assess ligand/CNB interaction, 1D and waterLOGSY experiments were performed on each compound (50 µM) 
in the presence or absence of 2.5 µM EPAC-CNB. In the absence of protein, each test compound produced a 
well-resolved 1D spectrum and a region of each spectrum was chosen to display distinctive spectral peaks orig-
inating from the ligand (Fig. 6). In the absence of protein, the corresponding waterLOGSY peaks were small, 
or absent, due to the negligible signal produced by saturation transfer from water to the freely tumbling small 
molecule. In the presence of EPAC1-CNB and EPAC2-CNB the peaks originating from I942 (Fig. 6A) and I178 
(Fig. 6B) became broadened, indicating that the compounds interact with the added CNBs. No peak broadening 
was observed for either compound in the presence of GST protein alone, indication that ligand interaction with 
the EPAC-CNBs was specific. In waterLOGSY spectra, protein-mediated saturation transfer can only occur if 
the protein-ligand complex has a substantial lifetime. Moreover, saturation transfer from 1H2O to the ligand 
that is mediated by the protein is of an opposing sign compared to direct transfer from water. As a result, the 
waterLOGSY signal obtained from a compound in the presence of a protein with which it interacts displays char-
acteristic inverted peaks. We found this to be the case for I942 and I178 in the presence of the EPAC-CNBs, but 
not in the presence of GST alone (Fig. 6A and B). Interestingly, I942’s signals were broadened (1D) and inverted 
(waterLOGSY) in the presence of both EPAC1-CNB and EPAC2-CNB (Fig. 6A). In contrast, I178 appeared to 
bind selectively to EPAC1-CNB (Fig. 6B), since its 1D NMR signals were heavily broadened in the presence of 
Figure 5. I942 and I178 have reduced Agonist Potential against EPAC2 Compared with EPAC1. (a) Time trace 
of the exchange reaction with recombinant EPAC2280–993 with cAMP (50 μM), I942 (500 μM) or a combination 
of cAMP (50 μM) and I942 (500 μM). (b) Rate constants from exchange reactions (n = 4)in the presence of I942 
(500 μM), I178 (500 μM) and/or cAMP (50 μM). (c) Inhibition of cAMP induces exchange activity of Epac2280–
993. kobs were determined in the presence of 50 μM cAMP and various concentrations of I942 and I178.
www.nature.com/scientificreports/
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EPAC1-CNB, but only slightly attenuated in the presence of EPAC2-CNBD, and it gave rise to waterLOGSY peaks 
with EPAC1-CNB, but not with EPAC2-CNB.
In order to test the manner in which each compound interacts with the EPAC-CNBs, 1D and waterLOGSY 
experiments were performed on ligand (50 µM)/protein (2.5 µM) complexes in the presence of saturating levels 
Figure 6. Ligand Observed NMR reveals Hit compounds Interact Directly with EPAC1-CNB and EPAC2-
CNB, but not GST alone. (A) One dimensional proton (1D) and waterLOGSY (WL) spectra were performed 
on samples containing hit compound I942 (50 µM) in the absence and presence of EPAC1-CNB, EPAC2-CNB 
or GST alone, as indicated (2.5 µM). A representative region of the I942 spectrum is shown (7.1–7.75 ppm). 
Interaction between compound and protein was assessed through comparison of the compound alone and 
protein-compound sample spectra. The NMR data are representative of data collected at several protein and 
ligand concentrations. (B) 1D and WL spectra were performed on samples containing I178 (50 µM) in the 
absence and presence of EPAC1-CNB, EPAC2-CNB or GST alone, as indicated (2.5 µM). A representative 
region of the I178 spectrum is shown (7.1–7.51 ppm). (C) 1D and WL spectra were performed on samples 
containing the commercially available EPAC selective inhibitor ESI-09 (50 µM) in the absence and presence of 
EPAC1-CNB, EPAC2-CNB or GST alone, as indicated (2.5 µM). A representative region of the ESI-09 spectrum 
is shown (0.6–1.2 ppm).
www.nature.com/scientificreports/
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of cAMP (1 mM). Consistent with competition observed in the presence of cAMP during HTS, the 1D peak 
broadening associated with compound-protein interaction was partially reversed in the presence of saturating 
concentrations of cAMP (Fig. 6). This reversibility indicates that cAMP is able to displace I178 or I942 from 
interacting with the CNB and that the displacement of 8-NBD-cAMP by I178 and I942 seen in HTS (Fig. 3) is 
unlikely to occur as a result of protein denaturation or other, non-specific effects. No reversal of the waterLOGSY 
peaks was observed in the presence of saturating levels of cAMP, likely due to the long mixing times employed by 
this technique and fast kinetics of binding (data not shown). In addition, interaction between the commercially 
available EPAC inhibitor, ESI-09, and EPAC1-CNB, EPAC2-CNB or GST alone (Fig. 6C) was tested. We found 
that 1D ESI-09 peak intensity was attenuated in the presence of EPAC1-CNB, EPAC2-CNB and GST alone, indi-
cating that ESI-09 may interact non-specifically with GST. The absence of an inverted ESI-09 peak in the pres-
ence of EPAC1-CNB can be attributed to compound binding with affinities beyond the threshold observable by 
waterLOGSY (sub-μM). Therefore, we conclude that both I178 and I942 interact with the EPAC1 CNB, with I178 
displaying greater selectivity for EPAC1 over EPAC2. Moreover, the commercially available compound, ESI-09, 
induces effects at lower concentrations than I178 or I942, but does appear to make non-specific protein inter-
actions. This is in agreement with the reported therapeutic window of ESI-09, where non-specific effects were 
observed at high concentrations33.
Discussion
We have demonstrated that an 8-NBD-cAMP HTS competition assay can be performed using the isolated 
CNB of EPAC1. By optimising buffer conditions, incubation times and the concentrations of EPAC1-CNB and 
8-NBD-cAMP in the assay, we were able to improve the sensitivity and power of the EPAC1-CNB assay for HTS. 
Subsequently, HTS of compound libraries identified two partial agonists towards EPAC1, I942 and I178. Such 
activation behaviour is also observed with several cAMP-analogues and is related to the activation mechanisms of 
EPAC26, 34. The core of the CNB domain blocks the access of Rap GTPases to the catalytic site in the auto-inhibited 
state of EPAC, which is referred to as the closed state35. cAMP is able to bind the CNB domain in the closed 
state, mainly through interactions with its phosphate sugar moiety. This initial binding causes small conforma-
tional rearrangements within the core of the CNB domain while EPAC remains in the auto-inhibited closed state. 
However, the core of the CNB domain is now free to tumble relative to the remaining part of the protein. This 
allows EPAC to adopt its open active sate. In the active state, the catalytic site is freely accessible to Rap GTPases. 
The CNB domain is localised at the “back” of the protein. The base of cAMP forms additional interaction with the 
“back” and thereby traps the core of the CNB domain at its position in the open active state36. Thus, in fact EPAC 
exists in equilibrium between inactive closed and active open conformations. This equilibrium is shifted to the 
active side upon binding of an agonist. The ability of the agonist to induce the conformational rearrangements in 
the core of the CNB domain, as a requirement for the movement of the domain, and to interact with the “back” 
of the protein, to stabilise the open active state, determines the extent to what the conformational equilibrium is 
shifted to the active side. Partial agonists are less efficient than cAMP in shifting the conformational equilibrium.
This also explains the apparent discrepancy regarding the affinity of I942 determined in the competition assay 
used for HTS (Fig. 3) and the activation assay (Fig. 4). The competition assay was performed with the isolated 
CNB domain. Binding of cAMP to the isolated CNB domain reflects only the initial binding of cAMP in the inac-
tive closed conformation. The interactions of cAMP with the “back” are not present in the isolated CNB domain. 
Likewise, contributions of the re-localisation of the CNB domains to the change in the Gibbs free energy are 
lacking. The affinities of the isolated CNB domain and of full EPAC1 were therefore found to be 4 μM and 40 μM, 
respectively30, 37. In the competition assay the affinity of I942 was found to be about 10 fold lower than that of 
cAMP, and thus to be about 40 μM. In the activation assay, the affinity of I942 was determined to be 50 μM and to 
be roughly the same as that of cAMP. I942 therefore binds to the isolated CNB domain and to full-length EPAC1 
with very similar affinities. Since I942 is a poor agonist, EPAC1 stays mainly in the closed conformation upon 
I942 binding and, therefore, the isolated CNB domain reflects this binding mode of I942 well. The partial agonist 
properties of I942 and I178 described here provide proof of concept that non-cyclic nucleotide EPAC agonists can 
now begin to be developed as tool molecules with the potential for future development into therapeutic agents.
Methods
Materials. Forskolin, rolipram, MG132 and cAMP were purchased from Merck-Millipore. Analogues of 
cAMP, 8-NBD-cAMP, 8-CPT-cAMP (8-CPT) and 8-pCPT-2′-O-Me-cAMP (007) were purchased from Biolog 
Life Sciences Institute (Bremen, Germany). The pGEX-6P-1 constructs, EPAC1-CNB and EPAC2-CNB, were 
prepared by Dundee Cell Products (Dundee, Scotland). BL-21 cells were purchased from New England Biolabs. 
The test compounds I288 (N-[(4-chlorophenyl)sulfonyl]-2-(1-naphthyloxy)acetamide) and I516 (2-[3-(acetyl-
amino)phenoxy]-N-[(4-methylphenyl)sulfonyl]acetamide) were purchased from ChemBridge Corporation (San 
Diego, CA, USA), whereas I178 (N-(benzenesulfonyl)-2-(naphthalen-2-yloxy)acetamide) and I942 (N-(2,4-
dimethylbenzenesulfonyl)-2-(naphthalen-2-yloxy)acetamide) were sourced from MolPort (Riga, Latvia).
Recombinant Protein purification. EPAC1-CNB (amino acids 169–318 of EPAC1) and EPAC2-CNB 
(amino acids 304–453 of EPAC2) cDNAs were sub-cloned into the multi-cloning site of the pGEX-6P-1 expres-
sion vector (Invitrogen). Recombinant GST-fusion proteins were then expressed and purified from BL-21 
Escherichia coli, as previously described34, 38. The purification of recombinant EPAC1 (149–881), EPAC2 (280–
993) and Rap1b (1–167) from bacteria was done as previously described29. Protein concentrations were deter-
mined by the bicinchoninic acid (BCA) assay or absorbance at 280 nm. All recombinant proteins were determined 
to be pure by SDS-PAGE analysis. Proteins were stored in aliquots at −80 °C until required.
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8-NBD-cAMP Competition Assay. Optimisation of 8-(2-[7-nitro-4-benzofurazanyl] aminoethylthio) 
adenosine-3′,5′-cyclic monophosphate (8-NBD-cAMP) competition assay was performed with purified 
EPAC1-CNB and EPAC2-CNB GST-fusion proteins, using modified assay conditions that were previously 
described21. Optimisation of assay conditions was performed in 96 well black assay plates (Greiner). Comparison 
of reference molecules, dose response curves and pilot screen were done in black, low volume 384 assay plates 
(Greiner). Liquids were dispensed using a Biomek Fx laboratory automation workstation with a 96-multichannel 
pipetting head (Beckman Coulter) for optimisation, whereas the Echo® Liquid Handler (Labcyte) and Wellmate 
automated dispenser (Thermo Matrix) were employed for pilot screens (see library screening). Plates were incu-
bated for four hours before 8-NBD-cAMP fluorescence intensity at 480/535 nm (ex/em) was measured using the 
Envision multi-label plate reader (Perkin-Elmer).
Compound Library Screening. A customised selection of structurally diverse drug-like compounds were 
obtained from the BioAscent Compound Cloud (www.bioascent.com/compoundcloud/, BioAscent, Biocity 
Scotland, Newhouse, Scotland) and were incubated with EPAC1-CNB to test for their ability to compete with 
8-NBD-cAMP binding to the CNB. This was done using the optimised assay conditions developed during 
the study. Library compounds were transferred from pre-prepared, 1000x stock Echo® 384 LDV source plates 
(Labcyte) into black, low volume 384 assay plates (Greiner) at 25 nl volumes, using an Echo® Liquid Handler 
(Labcyte), maintaining 0.1–1% DMSO throughout. EPAC1-CNB (0.8 µM) was immediately added using a 
Wellmate automated dispenser (Thermo Matrix). Plates were centrifuged at 800 rpm, 10 s, and then incubated 
for 30 minutes, RT, to promote compound-protein complex formation. 8-NBD-cAMP was then added (62.5 nM) 
and the plates were then briefly centrifuged (800 × g for 10 seconds) to mix reagents. The assay was incubated at 
room temperature and the fluorescence intensity at 480/535 nm (ex/em) was measured after 4–15 hours using the 
Envision plate reader.
Nuclear Magnetic Resonance (NMR). All NMR spectra were recorded on a Bruker AVANCE IIIHD 600 
spectrometer equipped with a TCI cryoprobe at 285 K. Test compounds were prepared in deuterated DMSO and 
diluted to given experimental concentrations in NMR buffer (20 mM Na2PO4, pH 7.0, 50 mM NaCl, 0.1% (w/v) 
NaN3, 5% (v/v) D2O) with a final DMSO concentration below 0.1%. Stocks of cAMP and recombinant proteins 
were prepared in NMR buffer. One dimensional proton (1D) and waterLOGSY spectra were recorded for all 
compounds tested, using pulse sequences as previously described39. Data was processed using Bruker Topspin 
software.
In Vitro Guanine Nucleotide Exchange Factor (GEF) Activity Assay. EPAC1 and EPAC2 in vitro 
GEF activities were calculated as previously described29. Briefly, recombinant EPAC1 (amino acids 149–881) or 
EPAC2 (amino acids 280–993) were incubated at 100 nM with recombinant Rap1 (200 nM) preloaded with the 
fluorescent GDP analogue 2′/3′-O-(N-Methylanthraniloyl)guanosine 5-diphosphate (MANT-GDP) in the pres-
ence of 20 μM GDP and then the fluorescence intensity was measured at 360/450 nm (ex/em) over time. Multiple 
reactions were performed at cAMP/compound concentration varying between 0.1 and 10000 μM and curves were 
fit as single exponential decay to obtain kobs. AC50 or IC50 values were determined from the plots of kobs against the 
concentration of the agonist and antagonist, respectively Table 1.
Protein Kinase A (PKA) Assay. PKA activity was measured directly in cell extracts using the PKA Kinase 
Activity Assay Kit (Abcam) following the manufacturer’s instructions. Whole cell extracts were prepared from 
HEK293T cells stably expressing full-length human EPAC140 using Nuclear Extract Kit from Active Motif. Cells 
were washed in ice-cold PBS containing phosphatase inhibitors, scrapped into Eppendorf tubes and centrifuged 
at 200 × g at 4 °C for 5 minutes. Supernatants were discarded and the cell pellet was re-suspended in Complete 
Lysis Buffer containing 1 mM DTT, 1 mM PMSF and protease inhibitor cocktail (Roche) and then incubated for 
10 minutes on ice (on the rocking platform) followed by vortex and centrifugation at 13,00 × g at 4 °C for 20 min-
utes. Cell extracts were then transferred to fresh Eppendorf tubes, assayed for protein content and then stored 
at −80 °C. For PKA activity measurement, ≈2 μg of whole cell extract diluted in kinase buffer were treated with 
Experimental 
Techniques
EPAC1 EPAC2
I942 I178 I942 I178
8NBD-cAMP 
Competition Assays IC50 ≈ 35 μM IC50 ≈ 40 μM IC50 ≈ 35 μM IC50 ≈ 40 μM
GEF Activation (no 
cAMP) AC50 ≈ 50 μM AC50 ≈ 200 μM N/A N/A
GEF Inhibition 
(with cAMP) IC50 ≈ 300 μM IC50 ≈ 500 μM IC50 ≈ 110 μM IC50 ≈ 250 μM
NMR Strong, Specific Interaction
Strong, Specific 
Interaction
Strong, Specific 
Interaction
Weak, specific 
interaction
Table 1. Summary of I942 and I178 activities in vitro. The table shows the relative activities of I942 and I178 
against EPAC1 and EPAC2 in NMR, CNBD binding assays (8NBD-cAMP Competition Assays) and in vitro 
GEF activity assays, in the presence or absence of cAMP. IC50 refers to the ability of I942 and I178 to compete 
with 8NBD-cAMP binding to isolated CNBs or inhibit EPAC GEF activity in the presence of cAMP. AC50, refers 
to the ability of I942 and I178 to promote EPAC GEF activity in the absence of cAMP. N/A refers to the inability 
of I942 and I178 to promote GEF activity of EPAC2.
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1 µM cAMP and various concentrations (0.1 to 100 µM) of I942 or the PKA inhibitor, H-89, in an ELISA plate 
coated with PKA substrate peptide. Next, 10 μl of ATP was added to each well and incubated at 30 °C for 90 min, 
with gentle shaking. The reaction was stopped by aspirating the contents of each well and then 40 µl of PKA 
phosphospecific substrate antibody was added to each well and then the plate was covered with plastic wrap and 
incubated at room temperature for 60 min (with gentle shaking every 20 min). Wells were rinsed 4 times with 1 
x wash buffer (100 µl) and, after the final wash, the plate was inverted and dried on a clean paper towel to remove 
any remaining wash buffer. Anti-Rabbit IgG:HRP Conjugate (1:1000) was then added to each well and incubated 
at room temperature for 30 minutes with gentle shaking every 10 min. The wells were aspirated again and washed 
as described above. Next, 60 μl of the HRP substrate was added to each well and incubated for 30 minutes at room 
temperature. Stop solution was then added and the absorbance was measured in a plate reader at 450 nm.
Statistical Analyses. Statistical significance was determined using one-way analysis of variance (ANOVA) 
with Tukey post-tests. The coefficient of variance (%CV) for assays was calculated by dividing the standard devia-
tion of a given response by the mean signal intensity and then multiplying by 100. The signal to background ratio 
(S/B) was determined by dividing the mean maximum fluorescent signal (DMSO diluent control) by the mean 
minimum signal (saturating cAMP concentrations) to give the magnitude of the fluorescence change in the assay. 
The Z’ factor was also calculated from the minimum (n, cAMP) and maximum (p, DMSO) control values from 
the assay, together with the mean fluorescent values (μ) and their standard deviation (σ), using the following 
equation:
σ σ
µ µ
= − +
−
′Z p n
p n
(
( )
1 3 3 )
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